Delta-Fly Pharma Current Assets

What does Delta-Fly Pharma do? Delta-Fly Pharma Inc generates revenue through the manufacturing and sale of pharmaceutical products focused on cancer treatment. The company develops and markets anticancer drug candidates including DFP-10917 for refractory or recurrent acute myelogenous leukemia, DFP-14323 for lung cancer, DFP-11207 for solid cancer, DFP-14927 for solid cancer or blood cancer, and DFP-10825 for peritoneal dissemination metastatic cancer. These products target medical professionals and healthcare institutions seeking innovative cancer therapies. The company's pipeline reflects a strategic focus on oncology with multiple candidates addressing specific cancer types. Delta-Fly Pharma Inc's business model relies on the research, development, and commercialization of its pharmaceutical pipeline. The firm's products are designed to address unmet medical needs in oncology, particularly for difficult-to-treat cancer conditions. By targeting specific cancer types with its drug candidates, the company aims to secure partnerships with healthcare providers and potentially pharmaceutical distributors. The development of DFP-10917, DFP-14323, DFP-11207, DFP-14927, and DFP-10825 represents the core of its revenue-generating activities. The company's revenue streams are derived from the sale of its pharmaceutical products once they reach commercialization. Currently, the company is in the development phase with its drug candidates, meaning revenue is primarily generated through research and development activities. The firm's pipeline includes five distinct anticancer drug candidates targeting various cancer types, which form the foundation of its business strategy. Delta-Fly Pharma Inc's focus on cancer treatment positions it within the pharmaceutical sector targeting healthcare providers and institutions. Delta-Fly Pharma is one of the most popular companies on Eulerpool.